HK1106227A1 - Crystalline form of a biphenyl compound - Google Patents
Crystalline form of a biphenyl compoundInfo
- Publication number
- HK1106227A1 HK1106227A1 HK07111424.6A HK07111424A HK1106227A1 HK 1106227 A1 HK1106227 A1 HK 1106227A1 HK 07111424 A HK07111424 A HK 07111424A HK 1106227 A1 HK1106227 A1 HK 1106227A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- salt
- crystalline form
- biphenyl compound
- hydroxy
- biphenyl
- Prior art date
Links
- 235000010290 biphenyl Nutrition 0.000 title 1
- 239000004305 biphenyl Substances 0.000 title 1
- -1 biphenyl compound Chemical class 0.000 title 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 4
- 208000019693 Lung disease Diseases 0.000 abstract 1
- URWYQGVSPQJGGB-DHUJRADRSA-N [1-[3-[2-chloro-4-[[[(2r)-2-hydroxy-2-(8-hydroxy-2-oxo-1h-quinolin-5-yl)ethyl]amino]methyl]-5-methoxyanilino]-3-oxopropyl]piperidin-4-yl] n-(2-phenylphenyl)carbamate Chemical compound ClC=1C=C(CNC[C@H](O)C=2C=3C=CC(=O)NC=3C(O)=CC=2)C(OC)=CC=1NC(=O)CCN(CC1)CCC1OC(=O)NC1=CC=CC=C1C1=CC=CC=C1 URWYQGVSPQJGGB-DHUJRADRSA-N 0.000 abstract 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical class OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60180504P | 2004-08-16 | 2004-08-16 | |
| PCT/US2005/029013 WO2006023454A1 (fr) | 2004-08-16 | 2005-08-15 | Forme cristalline de compose biphenyle |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1106227A1 true HK1106227A1 (en) | 2008-03-07 |
Family
ID=35687428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK07111424.6A HK1106227A1 (en) | 2004-08-16 | 2007-10-23 | Crystalline form of a biphenyl compound |
Country Status (26)
| Country | Link |
|---|---|
| US (4) | US7521558B2 (fr) |
| EP (1) | EP1778672B1 (fr) |
| JP (2) | JP5032990B2 (fr) |
| KR (1) | KR101363352B1 (fr) |
| CN (1) | CN101006077B (fr) |
| AR (1) | AR051003A1 (fr) |
| AU (1) | AU2005277601B2 (fr) |
| BR (1) | BRPI0514413C1 (fr) |
| CA (1) | CA2575874C (fr) |
| DK (1) | DK1778672T3 (fr) |
| ES (1) | ES2400958T3 (fr) |
| HK (1) | HK1106227A1 (fr) |
| HR (1) | HRP20130192T1 (fr) |
| IL (1) | IL180853A (fr) |
| MA (1) | MA28825B1 (fr) |
| MX (1) | MX2007001688A (fr) |
| MY (1) | MY141224A (fr) |
| NO (1) | NO338770B1 (fr) |
| NZ (1) | NZ552796A (fr) |
| PL (1) | PL1778672T3 (fr) |
| PT (1) | PT1778672E (fr) |
| RU (1) | RU2381223C2 (fr) |
| SI (1) | SI1778672T1 (fr) |
| TW (1) | TWI374883B (fr) |
| WO (1) | WO2006023454A1 (fr) |
| ZA (1) | ZA200701057B (fr) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6693202B1 (en) * | 1999-02-16 | 2004-02-17 | Theravance, Inc. | Muscarinic receptor antagonists |
| PE20040950A1 (es) * | 2003-02-14 | 2005-01-01 | Theravance Inc | DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS |
| TWI374883B (en) * | 2004-08-16 | 2012-10-21 | Theravance Inc | Crystalline form of a biphenyl compound |
| ES2265276B1 (es) | 2005-05-20 | 2008-02-01 | Laboratorios Almirall S.A. | Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico. |
| US8429052B2 (en) * | 2005-07-19 | 2013-04-23 | Lincoln National Life Insurance Company | Method and system for providing employer-sponsored retirement plan |
| GB0602778D0 (en) * | 2006-02-10 | 2006-03-22 | Glaxo Group Ltd | Novel compound |
| TW200811104A (en) * | 2006-04-25 | 2008-03-01 | Theravance Inc | Crystalline forms of a dimethylphenyl compound |
| TW200811105A (en) * | 2006-04-25 | 2008-03-01 | Theravance Inc | Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity |
| EA200900337A1 (ru) * | 2006-10-04 | 2009-10-30 | Пфайзер Лимитед | Сульфонамидные производные в качестве адренергических агонистов и мускариновых антагонистов |
| ES2302447B1 (es) * | 2006-10-20 | 2009-06-12 | Laboratorios Almirall S.A. | Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico. |
| ES2306595B1 (es) | 2007-02-09 | 2009-09-11 | Laboratorios Almirall S.A. | Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2. |
| ES2320961B1 (es) * | 2007-11-28 | 2010-03-17 | Laboratorios Almirall, S.A. | Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenergico beta2. |
| EP2096105A1 (fr) * | 2008-02-28 | 2009-09-02 | Laboratorios Almirall, S.A. | Dérivés de 4-(2-amino-1-hydroxyethyl)phénol en tant qu'antagonistes du récepteur adrénergique b2 |
| UY32297A (es) | 2008-12-22 | 2010-05-31 | Almirall Sa | Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico |
| EP2228368A1 (fr) | 2009-03-12 | 2010-09-15 | Almirall, S.A. | Procédé de fabrication de 5-(2-{[6-(2,2-difluoro-2-ph2nyl2thoxy)hexyl]amino}-1-hydroxy2thyl)-8-hydroxyquinolin-2(1h)-one |
| SG175023A1 (en) * | 2009-04-14 | 2011-11-28 | Glaxo Group Ltd | Process for the preparation of a biphenyl-2-ylcarbamic acid ester |
| RU2676686C2 (ru) | 2009-04-23 | 2019-01-10 | Тереванс Рэспирэйтори Кампани Эл Эл Си | ДИАМИДНЫЕ СОЕДИНЕНИЯ, ОБЛАДАЮЩИЕ АКТИВНОСТЬЮ АНТАГОНИСТА МУСКАРИНОВОГО РЕЦЕПТОРА И АКТИВНОСТЬЮ АГОНИСТА β2 АДРЕНЕРГИЧЕСКОГО РЕЦЕПТОРА |
| AU2015234331B2 (en) * | 2009-04-23 | 2017-08-03 | Theravance Biopharma R&D Ip, Llc | Diamide compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity |
| WO2011081937A1 (fr) | 2009-12-15 | 2011-07-07 | Gilead Sciences, Inc. | Composés de type corticostéroïde-bêta-agoniste-antagoniste muscarinique pour applications thérapeutiques |
| EP2386555A1 (fr) | 2010-05-13 | 2011-11-16 | Almirall, S.A. | Nouveaux dérivés de cyclohéxylamine dotés d'activités agoniste bêta 2 adrénergique et antagoniste muscarinique m3 |
| ITRM20110083U1 (it) | 2010-05-13 | 2011-11-14 | De La Cruz Jose Antonio Freire | Piastra per la costruzione di carrelli per aeroplani |
| GB201009801D0 (en) | 2010-06-11 | 2010-07-21 | Astrazeneca Ab | Compounds 950 |
| AR083115A1 (es) | 2010-09-30 | 2013-01-30 | Theravance Inc | Sales oxalato cristalinas de un compuesto diamida |
| EP2578570A1 (fr) | 2011-10-07 | 2013-04-10 | Almirall, S.A. | Nouveau procédé de fabrication de 5-(2-{[6-(2,2-difluoro-2-phényléthoxy)hexyl]amino}-1-hydroxyéthyl)-8-hydroxyquinolin-2(1h)-one via de nouveaux intermédiaires de synthèse |
| US9278099B2 (en) | 2011-10-31 | 2016-03-08 | Novartis Ag | Pazopanib formulation |
| EP2592077A1 (fr) | 2011-11-11 | 2013-05-15 | Almirall, S.A. | Nouveaux dérivés de cyclohéxylamine dotés d'activités agonistes bêta 2 adrénergique et antagoniste muscarinique M3 |
| EP2592078A1 (fr) | 2011-11-11 | 2013-05-15 | Almirall, S.A. | Nouveaux dérivés de cyclohéxylamine dotés d'activités agonistes bêta 2 adrénergique et antagoniste muscarinique M3 |
| EP2641900A1 (fr) | 2012-03-20 | 2013-09-25 | Almirall, S.A. | Nouvelles formes polymorphes de héminapadisylate de 5-(2-{[6-(2,2-difluoro-2-phényléthoxy) hexyl]amino}-1-(R)-hydroxyéthyl)-8-hydroxyquinolin-2(1h)-one en tant qu'agoniste du récepteur adrénergique ß2 |
| AP2015008573A0 (en) | 2012-12-18 | 2015-07-31 | Almirall Sa | New cyclohexyl and quinuclidinyl carbamate derivatives having beta 2 adrenergic agonist and M3 muscarinic antagonsit activity |
| TWI643853B (zh) | 2013-02-27 | 2018-12-11 | 阿爾米雷爾有限公司 | 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類 |
| TW201517906A (zh) | 2013-07-25 | 2015-05-16 | Almirall Sa | 含有ｍａｂａ化合物和皮質類固醇之組合 |
| TWI641373B (zh) | 2013-07-25 | 2018-11-21 | 阿爾米雷爾有限公司 | 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽 |
| TW201617343A (zh) | 2014-09-26 | 2016-05-16 | 阿爾米雷爾有限公司 | 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物 |
| TW201835041A (zh) | 2017-02-17 | 2018-10-01 | 印度商托仁特生技有限公司 | 具β-腎上腺素促效劑及抗蕈毒活性化合物 |
| WO2020047225A1 (fr) | 2018-08-30 | 2020-03-05 | Theravance Biopharma R&D Ip, Llc | Procédés de traitement de bronchopneumopathie chronique obstructive |
| WO2022175982A1 (fr) * | 2021-02-19 | 2022-08-25 | Gbr Laboratories Private Limited | Procédé de préparation de batéfentérol et de ses intermédiaires |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS596860B2 (ja) * | 1975-05-19 | 1984-02-15 | オオツカセイヤク カブシキガイシヤ | ５−〔（２−アルキルアミノ−１−ヒドロキシ）アルキル〕カルボスチリル誘導体の製造法 |
| US6362371B1 (en) | 1998-06-08 | 2002-03-26 | Advanced Medicine, Inc. | β2- adrenergic receptor agonists |
| EP1235802B1 (fr) | 1999-12-07 | 2005-07-13 | Theravance, Inc. | Derives de carbamate presentant une activite antagoniste du recepteur muscarinique |
| UA73543C2 (uk) | 1999-12-07 | 2005-08-15 | Тераванс, Інк. | Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором |
| US20030018019A1 (en) * | 2001-06-23 | 2003-01-23 | Boehringer Ingelheim Pharma Kg | Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics |
| US6653323B2 (en) * | 2001-11-13 | 2003-11-25 | Theravance, Inc. | Aryl aniline β2 adrenergic receptor agonists |
| PE20040950A1 (es) | 2003-02-14 | 2005-01-01 | Theravance Inc | DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS |
| JP2004356517A (ja) | 2003-05-30 | 2004-12-16 | Ebara Corp | 基板洗浄装置及び基板洗浄方法 |
| US20050025718A1 (en) * | 2003-07-31 | 2005-02-03 | Boehringer Ingelheim International Gmbh | Medicaments for inhalation comprising an anticholinergic and a betamimetic |
| US7320990B2 (en) * | 2004-02-13 | 2008-01-22 | Theravance, Inc. | Crystalline form of a biphenyl compound |
| TWI374883B (en) * | 2004-08-16 | 2012-10-21 | Theravance Inc | Crystalline form of a biphenyl compound |
-
2005
- 2005-08-03 TW TW094126435A patent/TWI374883B/zh not_active IP Right Cessation
- 2005-08-08 AR ARP050103308A patent/AR051003A1/es active IP Right Grant
- 2005-08-15 ES ES05803280T patent/ES2400958T3/es active Active
- 2005-08-15 PL PL05803280T patent/PL1778672T3/pl unknown
- 2005-08-15 SI SI200531675T patent/SI1778672T1/sl unknown
- 2005-08-15 NZ NZ552796A patent/NZ552796A/en not_active IP Right Cessation
- 2005-08-15 WO PCT/US2005/029013 patent/WO2006023454A1/fr active Application Filing
- 2005-08-15 JP JP2007527919A patent/JP5032990B2/ja not_active Expired - Fee Related
- 2005-08-15 AU AU2005277601A patent/AU2005277601B2/en not_active Ceased
- 2005-08-15 PT PT58032806T patent/PT1778672E/pt unknown
- 2005-08-15 RU RU2007109598/04A patent/RU2381223C2/ru active
- 2005-08-15 MX MX2007001688A patent/MX2007001688A/es active IP Right Grant
- 2005-08-15 US US11/204,065 patent/US7521558B2/en active Active
- 2005-08-15 CA CA2575874A patent/CA2575874C/fr active Active
- 2005-08-15 CN CN2005800281254A patent/CN101006077B/zh not_active Expired - Fee Related
- 2005-08-15 DK DK05803280.6T patent/DK1778672T3/da active
- 2005-08-15 EP EP05803280A patent/EP1778672B1/fr active Active
- 2005-08-15 BR BRPI0514413A patent/BRPI0514413C1/pt not_active IP Right Cessation
- 2005-08-15 KR KR1020077005834A patent/KR101363352B1/ko active IP Right Grant
- 2005-08-15 MY MYPI20053814A patent/MY141224A/en unknown
-
2007
- 2007-01-22 IL IL180853A patent/IL180853A/en active IP Right Grant
- 2007-02-05 ZA ZA200701057A patent/ZA200701057B/xx unknown
- 2007-02-23 MA MA29717A patent/MA28825B1/fr unknown
- 2007-03-09 NO NO20071307A patent/NO338770B1/no unknown
- 2007-10-23 HK HK07111424.6A patent/HK1106227A1/xx not_active IP Right Cessation
-
2009
- 2009-02-11 US US12/369,605 patent/US8101766B2/en not_active Expired - Fee Related
-
2011
- 2011-12-16 US US13/328,386 patent/US8476299B2/en active Active
-
2012
- 2012-03-22 JP JP2012065767A patent/JP2012121929A/ja not_active Withdrawn
-
2013
- 2013-03-05 HR HRP20130192TT patent/HRP20130192T1/hr unknown
- 2013-06-05 US US13/910,708 patent/US8754223B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW200613296A (en) | Crystalline form of a biphenyl compound | |
| TW200800948A (en) | Novel compound | |
| WO2007127297A3 (fr) | Formes cristallines d'un composé de diméthylphényle | |
| TW200714586A (en) | Crystalline forms of a biphenyl compound | |
| BRPI0906104A2 (pt) | "derivado de ácido nuclêico peptídico, composição farmacêutica contendo uma quantidade "terapeuticamente eficaz do derivado de ácido nuclêico peptídico, composição farmacêutica contendo uma quantidade terapeuticamente eficaz do derivado de ácido nuclêico peptídico,método de utilização do derivado de ácido nuclêico peptídico e composto" | |
| NO20091620L (no) | Boronsyre og estere som inhibitorer av fettsyreamidhydrolaser | |
| NO20080122L (no) | Blanding av diisononylestere av 1,2syklodikarbonsyrer, fremgangsmate for dere fremstilling og anvendelse derav | |
| MY174452A (en) | Substituted piperidines that increase p53 activity and the uses thereof | |
| EA201390481A1 (ru) | Кристаллические оксалатные соли диамидного соединения | |
| WO2008050199A8 (fr) | Composés de phénylméthyl bicyclocarboxyamide substitués | |
| MY151229A (en) | Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound | |
| SG10201407913UA (en) | Crystalline freebase forms of a biphenyl compound | |
| PT2049480E (pt) | Derivados de 2-arilindole como inibidores da mpges-i | |
| WO2005123679A3 (fr) | Nouveaux derives de piperidine substitues par alkyle et leur utilisation comme inhibiteurs de recaptage de neurotransmetteur de monoamine | |
| EP1780207A3 (fr) | Hydrate cristallin de esomeprazole de strontium, son procédé de préparation et composition pharmaceutique le contenant | |
| WO2005123670A3 (fr) | Forme cristalline d'un compose de pyrrolidine substituee | |
| TW200609233A (en) | Racemization method | |
| CY1113646T1 (el) | Κρυσταλλικη μορφη μιας ενωσης διφαινυλιου | |
| PL374489A1 (en) | Novel substituted arylhexadienoic acids and esters thereof which can be used for the treatment and prevention of diabetes, dyslipidaemia and atherosclerosis, pharmaceutical compositions comprising them and processes for the preparation of them |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20230815 |